Business Wire

The Royal Commission for AlUla Launches Its Second Winter at Tantora Festival of Culture, Heritage and Celebration in Saudi Arabia

20.12.2019 00:21:00 EET | Business Wire | Press release

Share

The second Winter at Tantora Festival in AlUla in North West Saudi Arabia starts today – a three-month celebration that will showcase the very best in international music, art and culture connecting East and West as the AlUla county has done for thousands of years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005781/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Winter at Tantora: Experience AlUla (Photo : AETOSWire)

It comes just months after Saudi Arabia introduced tourist visas to citizens from 49 countries making the Kingdom more accessible than ever with the UNESCO World Heritage site at Hegra in AlUla among those featured in a global marketing campaign.

The festival is part of the Cultural Manifesto that was launched by the festival organisers, the Royal Commission for AlUla, in Paris in October as part of a long-term strategy to transform the region and open the region as a global living museum and place of culture, heritage and the arts.

Winter at Tantora will cover 12 weekends from 19th December and host a wide range of events from the world-famous Dakar Rally; international ballooning festival; the world’s second longest endurance horse race; the world’s first desert polo tournament and welcome pop-up restaurants from globally renowned restaurants.

The spectacular mirrored wall Maraya Theatre with its 500-seat capacity and operatic sound quality will be home throughout the festival to some of the world’s leading performers who range from Omar Khairat to Andrea Bocelli.

Festival visitors will also be able to meet and engage with young members of the AlUla community who are benefitting from a diverse range of training programmes in hospitality; culture; nature and the environment and studying overseas including 24 men and women at the FERRANDI Paris culinary institute in Paris.

These young chefs will work alongside Michelin-starred experts during the festival creating world-class cuisine that will incorporate local ingredients from the fertile AlUla valley and blending traditional recipes with modern cuisine.

RCU CEO Amr AlMadani says: “Festival visitors will be given a unique opportunity to visit and experience one of the world’s undiscovered places and its spectacular heritage sites before we reopen them to the world in October 2020.

“They will get a tantalising glimpse of a place that been a cultural crossroads for thousands of years and the chance to see it from the serenity of a hot air balloon; the adrenaline of soaring over the desert and mountains in an open seater biplane or exploring hidden canyons in traditional vintage Land Rovers.”

The Royal Commission for AlUla has also completed major infrastructure work at AlUla airport – increasing capacity fourfold to 400,000 visitors a year and upgrading local mountain resorts to enhance the visitor experience.

AlUla will be a worldwide destination for those seeking a unique experience of the full meaning and context of landscape – an experience that integrates the natural and cultural heritage as one living environment. By safeguarding our precious landscapes and cultural heritage this open-air museum will be the Kingdom’s gift to the world creating remarkable and lasting memories.

‘Authentic AlUla’, the opening weekend, is a celebration rooted in AlUla, to mark the start of the winter planting season at the iconic Tantora sundial from which the festival is named. It is the first of 12 specially themed weekends.

Notes to editors

To find out more about the Winter at Tantora festival and details of packages and the entertainment and cultural programmes, log on to www.experiencealula.com

To find out more about how the Royal Commission for AlUla is working with the community to develop a world-class tourism destination, log on to www.rcu.gov.sa

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

RCU Public Relations team
The head of PR at RCU
Antony Newton
PublicRelations@rcu.gov.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye